Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 7052560, 17 pages
https://doi.org/10.1155/2017/7052560
Research Article

Therapeutic Effects of Methanol Extract from Euphorbia kansui Radix on Imiquimod-Induced Psoriasis

1College of Pharmacy, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul 06974, Republic of Korea
2College of Pharmacy, Dankook University, 119 Dandae-ro, Dongnam-gu, Cheonan-si, Chungnam 31116, Republic of Korea
3College of Medicine, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul 06974, Republic of Korea

Correspondence should be addressed to Kwang Woo Hwang; rk.ca.uac@gnawhk

Received 18 January 2017; Revised 22 April 2017; Accepted 7 May 2017; Published 2 July 2017

Academic Editor: Daniel Ortuño-Sahagún

Copyright © 2017 Soo Jeong Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. B. Gottlieb and J. G. Krueger, “HLA region genes and immune activation in the pathogenesis of psoriasis,” Archives of Dermatology, vol. 126, no. 8, pp. 1083–1086, 1990. View at Publisher · View at Google Scholar · View at Scopus
  2. J. M. Lemire, D. C. Archer, L. Beck, and H. L. Spiegelberg, “Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions,” The Journal of Nutrition, vol. 125, no. 6 Supplement, pp. 1704S–1708S, 1995. View at Google Scholar
  3. E. Fitch, E. Harper, I. Skorcheva, S. E. Kurtz, and A. Blauvelt, “Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines,” Current Rheumatology Reports, vol. 9, no. 6, pp. 461–467, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. P. C. Res, G. Piskin, O. J. de Boer et al., “Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis,” PloS One, vol. 5, no. 11, article e14108, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Abraham and J. Cho, “Interleukin-23/Th17 pathways and inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 15, no. 7, pp. 1090–1100, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. M. C. Boissier, E. Assier, G. Falgarone, and N. Bessis, “Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm,” Joint, Bone, Spine, vol. 75, no. 4, pp. 373–375, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Brucklacher-Waldert, K. Stuerner, M. Kolster, J. Wolthausen, and E. Tolosa, “Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis,” Brain, vol. 132, no. Part 12, pp. 3329–3341, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Di Cesare, P. Di Meglio, and F. O. Nestle, “The IL-23/Th17 axis in the immunopathogenesis of psoriasis,” The Journal of Investigative Dermatology, vol. 129, no. 6, pp. 1339–1350, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. A. Lowes, C. B. Russell, D. A. Martin, J. E. Towne, and J. G. Krueger, “The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses,” Trends in Immunology, vol. 34, no. 4, pp. 174–181, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. B. Gottlieb, “Immunologic mechanisms in psoriasis,” The Journal of Investigative Dermatology, vol. 95, no. 5 Supplement, pp. 18S–19S, 1990. View at Publisher · View at Google Scholar
  11. K. Uyemura, M. Yamamura, D. F. Fivenson, R. L. Modlin, and B. J. Nickoloff, “The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response,” The Journal of Investigative Dermatology, vol. 101, no. 5, pp. 701–705, 1993. View at Publisher · View at Google Scholar
  12. C. Ritchlin, S. A. Haas-Smith, D. Hicks, J. Cappuccio, C. K. Osterland, and R. J. Looney, “Patterns of cytokine production in psoriatic synovium,” The Journal of Rheumatology, vol. 25, no. 8, pp. 1544–1552, 1998. View at Google Scholar
  13. C. L. Leonardi, A. B. Kimball, K. A. Papp et al., “Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1),” Lancet, vol. 371, no. 9625, pp. 1665–1674, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Ritchlin, P. Rahman, A. Kavanaugh et al., “Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial,” Annals of the Rheumatic Diseases, vol. 73, no. 6, pp. 990–999, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. D. D. Patel, D. M. Lee, F. Kolbinger, and C. Antoni, “Effect of IL-17A blockade with secukinumab in autoimmune diseases,” Annals of the Rheumatic Diseases, vol. 72, Supplement 2, pp. ii116–ii123, 2013. View at Google Scholar
  16. C. Leonardi, R. Matheson, C. Zachariae et al., “Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis,” The New England Journal of Medicine, vol. 366, no. 13, pp. 1190–1199, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. W. Tausend, C. Downing, and S. Tyring, “Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab,” Journal of Cutaneous Medicine and Surgery, vol. 18, no. 3, pp. 156–169, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. B. W. Kirkham, A. Kavanaugh, and K. Reich, “Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis,” Immunology, vol. 141, no. 2, pp. 133–142, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. C. E. Griffiths, K. Reich, M. Lebwohl et al., “Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials,” Lancet, vol. 386, no. 9993, pp. 541–551, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. K. R. Beutner and A. Ferenczy, “Therapeutic approaches to genital warts,” The American Journal of Medicine, vol. 102, no. 5A, pp. 28–37, 1997. View at Google Scholar
  21. U. Patel, N. M. Mark, B. C. Machler, and V. J. Levine, “Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism,” The British Journal of Dermatology, vol. 164, no. 3, pp. 670–672, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. J. K. Wu, G. Siller, and G. Strutton, “Psoriasis induced by topical imiquimod,” The Australasian Journal of Dermatology, vol. 45, no. 1, pp. 47–50, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. P. A. Fanti, E. Dika, S. Vaccari, C. Miscial, and C. Varotti, “Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod,” International Journal of Dermatology, vol. 45, no. 12, pp. 1464-1465, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Q. Del Rosso, H. Sofen, B. Leshin, T. Meng, J. Kulp, and S. Levy, “Safety and efficacy of multiple 16-week courses of topical imiquimod for the treatment of large areas of skin involved with actinic keratoses,” The Journal of Clinical and Aesthetic Dermatology, vol. 2, no. 4, pp. 20–28, 2009. View at Google Scholar
  25. N. Rajan and J. A. Langtry, “Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas,” Clinical and Experimental Dermatology, vol. 31, no. 1, pp. 140-141, 2006. View at Publisher · View at Google Scholar
  26. L. van der Fits, S. Mourits, J. S. Voerman et al., “Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis,” Journal of Immunology, vol. 182, no. 9, pp. 5836–5845, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J. C. Waite and D. Skokos, “Th17 response and inflammatory autoimmune diseases,” International Journal of Inflammation, vol. 2012, Article ID 819467, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. H. L. Ha, H. Wang, P. Pisitkun et al., “IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 33, pp. E3422–E3431, 2014. View at Google Scholar
  29. P. R. Mangan, L. J. Su, V. Jenny et al., “Dual inhibition of interleukin-23 and interleukin-17 offers superior efficacy in mouse models of autoimmunity,” The Journal of Pharmacology and Experimental Therapeutics, vol. 354, no. 2, pp. 152–165, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Wohn, J. L. Ober-Blobaum, S. Haak et al., “Langerin(neg) conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 26, pp. 10723–10728, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. R. M. Andres, M. C. Montesinos, P. Navalon, M. Paya, and M. C. Terencio, “NF-kappaB and STAT3 inhibition as a therapeutic strategy in psoriasis: in vitro and in vivo effects of BTH,” The Journal of Investigative Dermatology, vol. 133, no. 10, pp. 2362–2371, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Mudigonda, T. Mudigonda, A. N. Feneran, H. S. Alamdari, L. Sandoval, and S. R. Feldman, “Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis,” Dermatology Online Journal, vol. 18, no. 10, p. 1, 2012. View at Google Scholar
  33. J. Shen, J. Kai, Y. Tang, L. Zhang, S. Su, and J. A. Duan, “The chemical and biological properties of Euphorbia kansui,” The American Journal of Chinese Medicine, vol. 44, no. 2, pp. 253–273, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. W. F. Zheng, Z. Cui, and Q. Zhu, “Cytotoxicity and antiviral activity of the compounds from Euphorbia kansui,” Planta Medica, vol. 64, no. 8, pp. 754–756, 1998. View at Google Scholar
  35. F. Cheng, Y. Yang, L. Zhang et al., “A natural triterpene derivative from Euphorbia kansui inhibits cell proliferation and induces apoptosis against rat intestinal epithelioid cell line in vitro,” International Journal of Molecular Sciences, vol. 16, no. 8, pp. 18956–18975, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Miyata, L. Y. Wang, C. Yoshida, and S. Kitanaka, “Inhibition of cellular proliferation by diterpenes, topoisomerase II inhibitor,” Bioorganic & Medicinal Chemistry, vol. 14, no. 6, pp. 2048–2051, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Oh, H. W. Oh, H. R. Lee et al., “Ingenane-type diterpene compounds from Euphorbia kansui modulate IFN-gamma production through NF-kappaB activation,” Journal of the Science of Food and Agriculture, vol. 96, no. 8, pp. 2635–2640, 2016. View at Publisher · View at Google Scholar · View at Scopus
  38. G. F. Passos, R. Medeiros, R. Marcon, A. F. Nascimento, J. B. Calixto, and L. F. Pianowski, “The role of PKC/ERK1/2 signaling in the anti-inflammatory effect of tetracyclic triterpene euphol on TPA-induced skin inflammation in mice,” European Journal of Pharmacology, vol. 698, no. 1–3, pp. 413–420, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. J. S. Chang, S. W. Lee, M. H. Park et al., “Kansuinine A and Kansuinine B from Euphorbia kansui L. inhibit IL-6-induced Stat3 activation,” Planta Medica, vol. 76, no. 14, pp. 1544–1549, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. L. C. Zaba, J. Fuentes-Duculan, N. J. Eungdamrong et al., “Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells,” The Journal of Investigative Dermatology, vol. 129, no. 1, pp. 79–88, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Tohyama, Y. Hanakawa, Y. Shirakata et al., “IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression,” European Journal of Immunology, vol. 39, no. 10, pp. 2779–2788, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Carrier, H. L. Ma, H. E. Ramon et al., “Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis,” The Journal of Investigative Dermatology, vol. 131, no. 12, pp. 2428–2437, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Homey, M. C. Dieu-Nosjean, A. Wiesenborn et al., “Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis,” Journal of Immunology, vol. 164, no. 12, pp. 6621–6632, 2000. View at Publisher · View at Google Scholar
  44. K. E. Nograles, L. C. Zaba, E. Guttman-Yassky et al., “Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways,” The British Journal of Dermatology, vol. 159, no. 5, pp. 1092–1102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. V. Romano, M. Angi, F. Scotti et al., “Inflammation and macular oedema after pars plana vitrectomy,” Mediators of Inflammation, vol. 2013, Article ID 971758, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. K. P. Moore and G. P. Aithal, “Guidelines on the management of ascites in cirrhosis,” Gut, vol. 55, Supplement 6, pp. vi1–v12, 2006. View at Google Scholar
  47. M. Ishizaki, T. Akimoto, R. Muromoto et al., “Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo,” Journal of Immunology, vol. 187, no. 1, pp. 181–189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. A. B. Van Belle, M. de Heusch, M. M. Lemaire et al., “IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice,” Journal of Immunology, vol. 188, no. 1, pp. 462–469, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Yanaba, M. Kamata, N. Ishiura et al., “Regulatory B cells suppress imiquimod-induced, psoriasis-like skin inflammation,” Journal of Leukocyte Biology, vol. 94, no. 4, pp. 563–573, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Cai, X. Shen, C. Ding et al., “Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation,” Immunity, vol. 35, no. 4, pp. 596–610, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. P. Di Meglio, A. Di Cesare, U. Laggner et al., “The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans,” PloS One, vol. 6, no. 2, article e17160, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Cuchacovich and L. R. Espinoza, “Lower level of synovial fluid interferon-gamma in HLA-B27-positive than in HLA-B27-negative patients with Chlamydia trachomatis reactive arthritis,” Rheumatology (Oxford), vol. 43, no. 2, pp. 249-250, 2004, author reply 250-241. View at Google Scholar
  53. S. A. Jones, C. E. Sutton, D. Cua, and K. H. Mills, “Therapeutic potential of targeting IL-17,” Nature Immunology, vol. 13, no. 11, pp. 1022–1025, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Brown, E. Wang, A. Leon et al., “Tumor necrosis factor-alpha inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience,” Journal of the American Academy of Dermatology, vol. 76, no. 2, pp. 334–341, 2017. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Joyau, G. Veyrac, V. Dixneuf, and P. Jolliet, “Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?” Clinical and Experimental Rheumatology, vol. 30, no. 5, pp. 700–706, 2012. View at Google Scholar
  56. R. Yoshiki, K. Kabashima, T. Honda et al., “IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing gammadelta T cells,” The Journal of Investigative Dermatology, vol. 134, no. 7, pp. 1912–1921, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. C. E. Sutton, L. A. Mielke, and K. H. Mills, “IL-17-producing gammadelta T cells and innate lymphoid cells,” European Journal of Immunology, vol. 42, no. 9, pp. 2221–2231, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. G. Piskin, U. Tursen, R. M. Sylva-Steenland, J. D. Bos, and M. B. Teunissen, “Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers—IL-12, IL-18 and IL-23,” Experimental Dermatology, vol. 13, no. 12, pp. 764–772, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. Y. Zheng, D. M. Danilenko, P. Valdez et al., “Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis,” Nature, vol. 445, no. 7128, pp. 648–651, 2007. View at Google Scholar
  60. R. M. Prins, N. Craft, K. W. Bruhn et al., “The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity,” Journal of Immunology, vol. 176, no. 1, pp. 157–164, 2006. View at Google Scholar
  61. M. A. Stanley, “Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential,” Clinical and Experimental Dermatology, vol. 27, no. 7, pp. 571–577, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Weber, C. Zimmermann, A. K. Mausberg, B. C. Kieseier, H. P. Hartung, and H. H. Hofstetter, “Induction of pro-inflammatory cytokine production in thymocytes by the immune response modifiers imiquimod and gardiquimod,” International Immunopharmacology, vol. 17, no. 2, pp. 427–431, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Patakas, R. A. Benson, D. R. Withers et al., “Th17 effector cells support B cell responses outside of germinal centres,” PloS One, vol. 7, no. 11, article e49715, 2012. View at Publisher · View at Google Scholar · View at Scopus